Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Daniela Meco, Nadia Trivieri, Anna Lasorella, Valentina Muto, Maurizio Martini, Marco Tartaglia, Matteo Lucchini, Alessandro Bruselles, Andrea Ciolfi, Massimo Caldarelli, Massimiliano Mirabella, Tiziana Servidei, Riccardo Riccardi, Roberta Morosetti
Publikováno v:
Cancer Research. 77:5860-5872
The basis for molecular and cellular heterogeneity in ependymomas of the central nervous system is not understood. This study suggests a basis for this phenomenon in the selection for mitogen-independent (MI) stem-like cells with impaired proliferati
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Autor:
Ilaria Conti, Sheng-Bin Peng, James J. Starling, Igor Mochalkin, Henry James Robert, Sean Buchanan, Robert D. Van Horn, Lysiane Huber, Gregory D. Plowman, Swee Seong Wong, Youyan Zhang, Vipin Yadav, Yong Gang Yue, Shih-Hsun Chen, Tinggui Yin
Publikováno v:
Cancer Discovery. 6:300-315
We have identified previously undiscovered BRAF in-frame deletions near the αC-helix region of the kinase domain in pancreatic, lung, ovarian, and thyroid cancers. These deletions are mutually exclusive with KRAS mutations and occur in 4.21% of KRAS
Autor:
Randall J. Kimple, Johan Lantto, Zachary S. Morris, David M. Francis, Craig R. Hullett, Eric A. Armstrong, Chunrong Li, Paul M. Harari, Lauryn R. Werner, Adam D. Swick, Michael Kragh, Shyhmin Huang
Publikováno v:
Clinical Cancer Research. 22:633-643
Purpose: Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers. Pan-HER represents a novel molecular targeted therapeutic composed of a mixture of six monoclonal anti
Autor:
Jason H. Cheng, Douglas Den Otter, Hani Bou-Reslan, Vidusha Devasthali, Richard A.D. Carano, Emily Chan, Klaus P. Hoeflich, Anne C Clermont, Michelle Nannini, Mallika Singh, Ciara Metcalfe, Mark Merchant, Dorothy French, Joseph Castillo, Melissa R. Junttila, Tim C. Cao, William F. Forrest
Publikováno v:
Molecular Cancer Therapeutics. 14:40-47
Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving malignant progression. Significant efforts to develop targeted inhibitors of nodes
Autor:
Stephen H. Friend, Brian Dougherty, Robert McEwen, Gilles Manceau, Pierre Laurent-Puig, Justin Guinney, Jonathan R. Dry, Erich Huang, Jean-Charles Soria, Michel Ducreux, Kai-Ming Chang, Jonathan M. J. Derry, KJ Kao, Charles Ferté, Kevin Hudson, Claus Bendtsen
Publikováno v:
Clinical Cancer Research. 20:265-272
Purpose: KRAS wild-type status is an imperfect predictor of sensitivity to anti-EGF receptor (EGFR) monoclonal antibodies in colorectal cancer, motivating efforts to identify novel molecular aberrations driving RAS. This study aimed to build a quanti